Biopharma developments over the Christmas period

Going into the 2021 festive period one key biotech catalyst remained: readout of Bridgebio’s phase 3 Attribute-CM study of acoramidis. Though Bridgebio’s stock had ticked up in previous days the trial’s result, unveiled on December 27, was a resounding failure, though it remains a mystery why placebo performed just as well as acoramidis.